Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Alnylam Pharmaceuticals reported $84.31M in Cost of Sales for its fiscal quarter ending in September of 2023.

Cost Of Sales Change Date
Acadia Pharmaceuticals USD 14.62M 7.16M Sep/2023
Agios Pharmaceuticals USD 633K 475K Sep/2023
Alnylam Pharmaceuticals USD 84.31M 1.06M Sep/2023
Amgen USD 1.81B 36M Sep/2023
BioCryst Pharmaceuticals USD 1.14M 186K Sep/2023
BioMarin Pharmaceutical USD 124.74M 3.34M Sep/2023
Bluebird Bio USD 10.96M 1.39M Sep/2023
Incyte USD 54.39M 8.24M Sep/2023
Ionis Pharmaceuticals USD 2.19M 346K Sep/2023
Moderna USD 2.24B 1.51B Sep/2023
Neurocrine Biosciences USD 11.2M 300K Sep/2023
PTC Therapeutics USD 9.49M 3.24M Sep/2023
Regeneron Pharmaceuticals USD 436.4M 31.5M Sep/2023
Sarepta Therapeutics USD 37.03M 2.9M Sep/2023
Takeda JPY 343.58B 22.47B Sep/2023
Ultragenyx Pharmaceutical USD 10.99M 1.07M Sep/2023
Vertex Pharmaceuticals USD 318.7M 10.1M Sep/2023